1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
3.2. Global Benign Prostatic Hyperplasia Treatment Market: Market Snapshot
4. Market Overview
4.1. Global Benign Prostatic Hyperplasia Treatment Market: Treatment Overview
4.2. Global Benign Prostatic Hyperplasia Treatment Market: Key Industry Developments
4.3. Market Dynamics
4.4. Drivers and Restraints Snapshot Analysis
4.5. Drivers
4.5.1. Increasing Aging Men Population All Over the World
4.5.2. Expanding Patient Pool Due to Other Risk Factors
4.6. Restraints
4.6.1. Insufficient Healthcare Facilities and Unawareness of BPH Condition
4.6.2. Patent Expiration of Benign Prostatic Hyperplasia Drugs
4.7. Opportunities
4.8. Global Benign Prostatic Hyperplasia Treatment Market Revenue Projections (US$ Mn), 2017-2027
5. Key Insights
5.1. Clinical Trial Pipeline Analysis
5.2. U.S. Prevalence of Benign Prostatic Hyperplasia
5.3. Re-imbursement Scenario
5.4. Key Merger and Acquisitions
5.5. Number of Surgeries (Unit Procedures) Performed, 2018
5.6. Competitive Market Share Analysis, by Company, 2018
5.7. Average Cost of Benign Prostatic Hyperplasia Treatment
5.8. Product/Brand Analysis - 2018
5.8.1. Urolift
5.8.2. Rezum
6. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
6.1. Introduction
6.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
6.2.1. Drug Class
6.2.1.1. Alpha-blockers
6.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
6.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
6.2.1.4. Others
6.2.2. Minimally Invasive Surgeries
6.2.2.1. Transurethral Resection of the Prostate (TURP)
6.2.2.2. Transurethral Incision of the Prostate (TUIP)
6.2.2.3. Robotic Surgeries
6.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
6.2.2.5. Prostatic Urethral Lift
6.2.2.6. Others
6.2.3. Laser Therapy
6.2.4. Others
6.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Treatment
6.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Treatment
7. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
7.1. Introduction
7.2. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
7.2.1. Hospitals
7.2.2. Ambulatory Surgical Centers
7.2.3. Specialty Clinics
7.2.4. Others
7.3. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by End-user
7.4. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by End-user
8. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
8.1. Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Region, 2017-2027
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Latin America
8.1.5. Middle East & Africa
8.2. Global Benign Prostatic Hyperplasia Treatment Market Analysis, by Region
8.3. Global Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis, by Region
9. North America Benign Prostatic Hyperplasia Treatment Market Analysis
9.1. North America Benign Prostatic Hyperplasia Treatment Market
9.2. North America Benign Prostatic Hyperplasia Treatment Market Overview
9.3. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
9.3.1. Drug Class
9.3.1.1. Alpha-blockers
9.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
9.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
9.3.1.4. Others
9.3.2. Minimally Invasive Surgeries
9.3.2.1. Transurethral Resection of the Prostate (TURP)
9.3.2.2. Transurethral Incision of the Prostate (TUIP)
9.3.2.3. Robotic Surgeries
9.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
9.3.2.5. Prostatic Urethral Lift
9.3.2.6. Others
9.3.3. Laser Therapy
9.3.4. Others
9.3.5.
9.4. North America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
9.4.1. Hospitals
9.4.2. Ambulatory Surgical Centers
9.4.3. Specialty Clinics
9.4.4. Others
9.5. North America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. North America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
9.6.1. By Treatment
9.6.2. By End-user
9.6.3. By Country
10. Europe Benign Prostatic Hyperplasia Treatment Market Analysis
10.1. Europe Benign Prostatic Hyperplasia Treatment Market
10.2. Europe Benign Prostatic Hyperplasia Treatment Market Overview
10.3. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
10.3.1. Drug Class
10.3.1.1. Alpha-blockers
10.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
10.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
10.3.1.4. Others
10.3.2. Minimally Invasive Surgeries
10.3.2.1. Transurethral Resection of the Prostate (TURP)
10.3.2.2. Transurethral Incision of the Prostate (TUIP)
10.3.2.3. Robotic Surgeries
10.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
10.3.2.5. Prostatic Urethral Lift
10.3.2.6. Others
10.3.3. Laser Therapy
10.3.4. Others
10.4. Europe Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
10.4.1. Hospitals
10.4.2. Ambulatory Surgical Centers
10.4.3. Specialty Clinics
10.4.4. Others
10.5. Europe Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
10.5.1. U.K.
10.5.2. France
10.5.3. Germany
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Europe Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis
11.1. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Key Findings
11.2. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Overview
11.3. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
11.3.1. Drug Class
11.3.1.1. Alpha-blockers
11.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
11.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
11.3.1.4. Others
11.3.2. Minimally Invasive Surgeries
11.3.2.1. Transurethral Resection of the Prostate (TURP)
11.3.2.2. Transurethral Incision of the Prostate (TUIP)
11.3.2.3. Robotic Surgeries
11.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
11.3.2.5. Prostatic Urethral Lift
11.3.2.6. Others
11.3.3. Laser Therapy
11.3.4. Others
11.4. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
11.4.1. Hospitals
11.4.2. Ambulatory Surgical Centers
11.4.3. Specialty Clinics
11.4.4. Others
11.5. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
11.5.1. China
11.5.2. India
11.5.3. Japan
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Benign Prostatic Hyperplasia Treatment Market Analysis
12.1. Latin America Benign Prostatic Hyperplasia Treatment Market Key Findings
12.2. Latin America Benign Prostatic Hyperplasia Treatment Market Overview
12.3. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
12.3.1. Drug Class
12.3.1.1. Alpha-blockers
12.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
12.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
12.3.1.4. Others
12.3.2. Minimally Invasive Surgeries
12.3.2.1. Transurethral Resection of the Prostate (TURP)
12.3.2.2. Transurethral Incision of the Prostate (TUIP)
12.3.2.3. Robotic Surgeries
12.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
12.3.2.5. Prostatic Urethral Lift
12.3.2.6. Others
12.3.3. Laser Therapy
12.3.4. Others
12.4. Latin America Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
12.4.1. Hospitals
12.4.2. Ambulatory Surgical Centers
12.4.3. Specialty Clinics
12.4.4. Others
12.5. Latin America Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Latin America Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Analysis
13.1. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market
13.2. Benign Prostatic Hyperplasia Treatment Market Overview
13.3. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by Treatment
13.3.1. Drug Class
13.3.1.1. Alpha-blockers
13.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
13.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
13.3.1.4. Others
13.3.2. Minimally Invasive Surgeries
13.3.2.1. Transurethral Resection of the Prostate (TURP)
13.3.2.2. Transurethral Incision of the Prostate (TUIP)
13.3.2.3. Robotic Surgeries
13.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
13.3.2.5. Prostatic Urethral Lift
13.3.2.6. Others
13.3.3. Laser Therapy
13.3.4. Others
13.4. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size and Forecast, by End-user
13.4.1. Hospitals
13.4.2. Ambulatory Surgical Centers
13.4.3. Specialty Clinics
13.4.4. Others
13.5. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Forecast, by Country/Sub-region
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competitive Landscape (Pharmaceutical Companies)
14.1. Company Profiles
14.1.1. Abbott
14.1.1.1. Overview (HQ, Employee Strength, Business Segments)
14.1.1.2. Financials
14.1.1.3. Recent Developments
14.1.1.4. Strategy
14.1.2. Allergan plc
14.1.2.1. Overview (HQ, Employee Strength, Business Segments)
14.1.2.2. Financials
14.1.2.3. Recent Developments
14.1.2.4. Strategy
14.1.3. Astellas Pharma, Inc.
14.1.3.1. Overview (HQ, Employee Strength, Business Segments)
14.1.3.2. Financials
14.1.3.3. Recent Developments
14.1.3.4. Strategy
14.1.4. Asahi Kasei Corporation
14.1.4.1. Overview (HQ, Employee Strength, Business Segments)
14.1.4.2. Financials
14.1.4.3. Recent Developments
14.1.4.4. Strategy
14.1.5. Boehringer Ingelheim GmbH
14.1.5.1. Overview (HQ, Employee Strength, Business Segments)
14.1.5.2. Financials
14.1.5.3. Recent Developments
14.1.5.4. Strategy
14.1.6. GlaxoSmithKline plc
14.1.6.1. Overview (HQ, Employee Strength, Business Segments)
14.1.6.2. Financials
14.1.6.3. Recent Developments
14.1.6.4. Strategy
14.1.7. Pfizer, Inc.
14.1.7.1. Overview (HQ, Employee Strength, Business Segments)
14.1.7.2. Financials
14.1.7.3. Recent Developments
14.1.7.4. Strategy
14.1.8. Sanofi
14.1.8.1. Overview (HQ, Employee Strength, Business Segments)
14.1.8.2. Financials
14.1.8.3. Recent Developments
14.1.8.4. Strategy
14.1.9. Teva Pharmaceutical Industries Ltd.
14.1.9.1. Overview (HQ, Employee Strength, Business Segments)
14.1.9.2. Financials
14.1.9.3. Recent Developments
14.1.9.4. Strategy
14.1.10. Merck & Co., Inc.
14.1.10.1. Overview (HQ, Employee Strength, Business Segments)
14.1.10.2. Financials
14.1.10.3. Recent Developments
14.1.10.4. Strategy
15. Competitive Landscape (Medical Devices/Service Provider Organizations)
15.1. Company Profiles
15.1.1. Boston Scientific Corporation
15.1.1.1. Overview (HQ, Employee Strength, Business Segments)
15.1.1.2. Financials
15.1.1.3. Recent Developments
15.1.1.4. Strategy
15.1.2. Teleflex Incorporated
15.1.2.1. Overview (HQ, Employee Strength, Business Segments)
15.1.2.2. Financials
15.1.2.3. Recent Developments
15.1.2.4. Strategy
15.1.3. Endo International plc
15.1.3.1. Overview (HQ, Employee Strength, Business Segments)
15.1.3.2. Financials
15.1.3.3. Recent Developments
15.1.3.4. Strategy
15.1.4. Urologix, LLC
15.1.4.1. Overview (HQ, Employee Strength, Business Segments)
15.1.4.2. Financials
15.1.4.3. Recent Developments
15.1.4.4. Strategy
15.1.5. LISA Laser
15.1.5.1. Overview (HQ, Employee Strength, Business Segments)
15.1.5.2. Financials
15.1.5.3. Recent Developments
15.1.5.4. Strategy
15.1.6. Olympus Corporation
15.1.6.1. Overview (HQ, Employee Strength, Business Segments)
15.1.6.2. Financials
15.1.6.3. Recent Developments
15.1.6.4. Strategy